Ajai Chari, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Professionals
Ajai Chari, MD

Ajai Chari, MD

Healthcare Professional / Researcher
Professor
Mount Sinai Ruttenberg Treatment Center
10 East 102nd Street
6th Floor
New York, New York, United States
Dr. Chari is a Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office. He completed his MD from University of California, Los Angeles School of Medicine (UCLA) followed by residency in Internal medicine from Columbia University Medical Center and Fellowship in Hematology and Oncology from  University of California – San Francisco. 
 
Ajai Chari has clinical interests in plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance (MGUS). Dr Chari has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally.
 
Dr. Chari’s research interests include the development of novel chemotherapy regimens, including phase 1 and 2 studies. He is principal investigator (PI) of several investigator-initiated trials as well as the national and international PI of several industry sponsored studies. 
 
 
 
 
view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close